Literature DB >> 2354927

Microvascular changes in rabbit kidneys after extracorporeal shock wave treatment.

L L Fajardo1, B J Hillman, C Weber, J M Donovan, G W Drach.   

Abstract

Concerns about the safety of extracorporeal shock wave lithotripsy include the risk of vascular damage and the genesis of hypertension. We evaluated gross specimens and barium microangiograms of the right kidneys of 14 rabbits exposed to shock waves; the untreated left kidneys served as controls. Six rabbits were assessed immediately after shock wave treatment, whereas the other eight rabbits had the same procedure 3 months later. All six acute phase animals showed microangiographic changes indicative of shock wave trauma, including cortical, subcapsular, and medullary extravasation of barium and patchy loss of efferent vessels. No significant vascular abnormalities were seen in the control kidneys. All kidneys treated from the animals that had delayed microangiography showed macroscopic evidence of fibrotic capsular thickening and parenchymal scarring. Microscopically, there was crowding of glomeruli and areas of avascularity. In this model, shock waves damaged the cortical circulation and resulted in persistent alterations of the microvasculature that potentially could be responsible for the abnormal secretion of renin.

Entities:  

Mesh:

Year:  1990        PMID: 2354927     DOI: 10.1097/00004424-199006000-00008

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Treatment of renal calculi by lithotripsy: minimizing short-term shock wave induced renal damage by using antioxidants.

Authors:  Khaleel A Al-Awadi; Elijah O Kehinde; Issa Loutfi; Olusegun A Mojiminiyi; Adel Al-Hunayan; Hamdy Abdul-Halim; Ahmed Al-Sarraf; Anjum Memon; Mathew P Abraham
Journal:  Urol Res       Date:  2007-12-07

Review 2.  Pediatric urolithiasis: review of research and current management.

Authors:  E P Harmon; D E Neal; R Thomas
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.